Department of Morphology and Genetics, Federal University of São Paulo, São Paulo, Brazil.
Department of Morphology, Dental School, Laboratory of Histology and Embryology, University Estadual Paulista, Araraquara, São Paulo, Brazil.
J Periodontol. 2017 Jan;88(1):100-111. doi: 10.1902/jop.2016.160132. Epub 2016 Sep 2.
Histamine seems to act, via H receptor, on inflammatory processes by stimulating interleukin (IL)-6 and matrix metalloproteinase (MMP) release. As cimetidine is an H receptor antagonist, the authors hypothesize that this antiulcer drug reduces IL-6, MMP-1, and MMP-9 immunoexpression in gingiva with induced periodontal disease (PD). To confirm a possible modulatory role of IL-6 on MMPs, the relationship between IL-6/MMP-1 and IL-6/MMP-9 immunoexpression was evaluated.
Forty-six male rats were distributed into the cimetidine group (CimG: received daily intraperitoneal injections of 100 mg/kg of body weight of cimetidine) or the saline group (SG). PD was induced by cotton ligature around the maxillary left first molars (PDSG and PDCimG). The right molars were used as controls (SG and CimG). After 7, 15, 30, and 50 days, maxillary fragments were processed for paraffin embedding or for transmission electron microscopy. Tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts in the alveolar process surface and number of IL-6, MMP-1, and MMP-9-immunolabeled cells in the gingival mucosa were quantified. Statistical analyses were performed (P ≤0.05).
In PDSG and PDCimG, gingival mucosa exhibited few collagen fibers among numerous inflammatory cells. In PDCimG, the number of TRAP-positive osteoclasts and IL-6, MMP-1, and MMP-9-immunolabeled cells was significantly lower than in PDSG at all periods. A positive correlation between IL-6/MMP-1 and IL-6/MMP-9 was detected in PDSG and PDCimG.
Cimetidine decreases bone loss through reduction of osteoclast number and induces reduction of IL-6, MMP-1, and MMP-9 immunoexpression, reinforcing the idea that the beneficial effect of cimetidine in PD may be due to reduction of IL-6 immunolabeling in the inflamed gingival mucosa.
组胺似乎通过 H 受体作用于炎症过程,刺激白细胞介素 (IL)-6 和基质金属蛋白酶 (MMP) 的释放。由于西咪替丁是 H 受体拮抗剂,作者假设这种抗溃疡药物会降低诱导牙周病 (PD) 后牙龈中的 IL-6、MMP-1 和 MMP-9 的免疫表达。为了证实 IL-6 对 MMPs 的可能调节作用,评估了 IL-6/MMP-1 和 IL-6/MMP-9 免疫表达之间的关系。
将 46 只雄性大鼠分为西咪替丁组 (CimG:每天腹腔注射 100mg/kg 体重的西咪替丁) 或生理盐水组 (SG)。通过在左上第一磨牙周围的棉线结扎诱导 PD (PDSG 和 PDCimG)。右侧磨牙用作对照 (SG 和 CimG)。7、15、30 和 50 天后,上颌骨碎片进行石蜡包埋或透射电镜处理。在牙槽突表面计数抗酒石酸酸性磷酸酶 (TRAP) 阳性破骨细胞和牙龈黏膜中 IL-6、MMP-1 和 MMP-9 免疫标记细胞的数量。进行了统计学分析 (P≤0.05)。
在 PDSG 和 PDCimG 中,牙龈黏膜中仅有少量胶原纤维,炎症细胞较多。在 PDCimG 中,与 PDSG 相比,所有时期的 TRAP 阳性破骨细胞和 IL-6、MMP-1 和 MMP-9 免疫标记细胞数量均显著降低。在 PDSG 和 PDCimG 中,检测到 IL-6/MMP-1 和 IL-6/MMP-9 之间存在正相关。
西咪替丁通过减少破骨细胞数量减少骨丢失,并诱导减少 IL-6、MMP-1 和 MMP-9 的免疫表达,这加强了西咪替丁在 PD 中的有益作用可能是由于减少了炎症牙龈黏膜中的 IL-6 免疫标记的观点。